Corcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow CORT
Corcept Therapeutics Incorporated (CORT) EV/Sales
As of 16 October 2026, Corcept Therapeutics Incorporated (CORT) trades at a EV/Sales of 13.6×. Over the past ten years it has ranged from 2.9× (April 2020) to 22.6× (March 2015); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.3× | (40.27%) |
| FY2024 | 7.2× | 61.11% |
| FY2023 | 4.4× | 3.09% |
| FY2022 | 4.3× | (24.02%) |
| FY2021 | 5.7× | (22.43%) |
| FY2020 | 7.3× | 100.27% |
| FY2019 | 3.7× | (31.91%) |
| FY2018 | 5.4× | (56.96%) |
| FY2017 | 12.5× | 29.85% |
| FY2016 | 9.6× | (6.79%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.7× | 111.25% |
| Mar 2026 | 5.1× | 18.13% |
| Dec 2025 | 4.3× | (61.33%) |
| Sep 2025 | 11.1× | 8.28% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. compare | 9.7× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 9.8× |
| CORT Corcept Therapeutics Incorporated | 13.6× |
| BBIO BridgeBio Pharma, Inc. compare | 19.9× |
| IBRX ImmunityBio, Inc. compare | 63.6× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)